Novel anti-infective treatments
Xellia is a specialty pharmaceutical company that provides anti-infective treatments and other critical care therapies for serious and often life-threatening conditions.
About us
Featured news
10 Sep 2024
Xellia Pharmaceuticals announces the completion of the divestment of its US-based institutional activities to Hikma Pharmaceuticals
Read article
17 Jun 2024
Xellia Pharmaceuticals to focus on the manufacturing and commercialization of its life-saving anti-infectives portfolio through its global B2B partners
Read articleXellia’s goal is to demonstrate excellence in innovative development and state-of-the-art manufacturing to meet the demands for anti-infective and critical care therapies for patients around the world
Who we are
Xellia is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections, focusing on the manufacturing and commercializing of fermentation-based anti-infective APIs (Active Pharmaceutical Ingredients).
Customers depend on us for reliable supply and consistent quality and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability.
Headquartered in Copenhagen, Denmark, and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1400 employees globally, including state-of-the-art manufacturing sites in China, Denmark, and Hungary. Our strong market position is built on more than 120 years of pharmaceutical industry experience.
